SR One, a trans-Atlantic biotech venture capital firm announced the close of its first independent fund after raising $500 million.
SR One Chief Executive Officer Simeon George and his team at SR One have also completed their spinout from its parent company GlaxoSmithKline (GSK).
However, GSK will remain as the largest investor in the oversubscribed $500 million fund, together with a global pool of institutional asset managers, endowments, foundations, pension funds and family offices.
SR One will seek to continue to build elite biotechnology companies developing innovative medicines that address significant unmet needs.
SR One Chief Executive Officer, Simeon George said, “Our spin-out from GSK and successful raise of a new independent fund provide a foundation for SR One’s next chapter, enabling us to scale our investment strategy and build upon our track record of success.
David Redfern, Chief Strategy Officer at GSK, noted, “GSK has remained a committed investor in SR One’s new independent fund. The close of the fund at the hard cap and its oversubscription by global investors underscore the team’s abilities and strong track record.”
Malayalee Simeon George, who holds M.D. and M.B.A,, has 15 years of experience in the biotechnology industry. He joined SR One in 2007 and established the San Francisco office in 2010. Simeon’s father, late Dr.John George was from the Pynumootil family in Thiruvalla. His mother Dr.Tahira George and uncle Dr.Simon George are based in the UK.
Simeon lives in San Francisco with his wife Noureen and three children.
